Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech that has worked vigilantly but unsuccessfully to develop an one off therapy, variously referred to as Pro 140, leronlimab, as well as Vyrologix.

In development of this treatment, CytoDyn has cast its net far and wide both geographically and in terminology of possible indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they’ll actually be used is an open question.

While CYDY  happens to be dawdling, promote opportunities for leronlimab as being a combination therapy in the curing of multi-drug-resistant HIV have been closing.

I am composing my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale of my past few shares. My first CytoDyn article, “CytoDyn: What to be able to Do When It’s Too Good In order to Be True?”, set away the following prediction:

Rather I expect it to become a serial disappointer. CEO Pourhassan offered such an extremely marketing picture in the Uptick Newswire employment interview that I came away with a bad impression of the business.

Irony of irony, the bad impression of mine of the business enterprise has grown steadily, however, the disappointment has not been financial. 2 years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades at $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is it that delivers a > six bagger yet still disappoints? Therein sits the story; let me explain.

CytoDyn acquired its much storied treatment (which I shall relate to as leronlimab) back during 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor for your treatment and avoidance of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical development mAb with demonstrated anti-viral activity in HIV infected subjects. Today’s transaction of $3.5 million transfers ownership of this know-how as well as connected intellectual property from Progenics to CytoDyn, and approximately 25 million mg of majority drug substance…. milestone payments after commencement of a phase III clinical trial ($1.5 million) as well as the very first new drug application endorsement ($5 million), and even royalty payments of 5 percent of net sales upon commercialization.

Since that point in time, CytoDyn’s leading nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition right into a springboard for CytoDyn to get a sector cap > $3.5 billion. It’s done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with many indications and numerous therapies, it has this single treatments as well as a “broad pipeline of indications” as it places it. I call such pipelines, “pipedots.” In CytoDyn’s situation it touts its leronlimab as a likely beneficial therapy in dozens of indications.

Its opening banner on its website (below) shows an energetic business with diverse interests albeit focused on leronlimab, multiple disease types, multiple publications and multiple delivering presentations.

Can it all be smoke cigarettes and mirrors? That’s a question I’ve been asking myself from the very start of my interest in this particular company. Judging by the multiples of a huge number of various commentary on listings accessible via Seeking Alpha’s CytoDyn Summary webpage, I am much from alone in this particular question.

CytoDyn is a traditional battleground, or even some could say cult stock. Its adherents are fiercely protective of the prospects of its, quick to label some negative opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *